HomeMost PopularImmix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum

Actionable Trade Ideas

always free

Creative image of embryonic stem cells

Intro

Immix Biopharma (NASDAQ:IMMX) got here public by way of a small IPO in 2021 as an early-stage oncology biotech growing therapeutics to ship small molecules deep into the tumor microenvironment. Then, in December 2022, the corporate quietly reworked itself by in-licensing NXC-201, a BCMA-targeting CAR-T

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.